Novavax COVID Vaccine Efficacy In Omicron, Delta Variants Among Unknowns Ahead Of Advisory Cmte
US FDA also says there appears to be 'causal association' of myocarditis with the vaccine, which Novavax denies.
You may also be interested in...
A US FDA advisory committee review of a novel COVID vaccine candidate from Novavax made one thing very clear: The agency is firmly convinced that when it comes to vaccine options, more is better.
Now that multiple vaccines using different platforms seem to be associated with heart inflammation, the FDA and others want more data on whether a common characteristic of the virus or vaccine manufacturing is related.
Vaccines and Related Biological Products Advisory Committee members agree another option should be made available, especially if Novavax's protein-based design could encourage those who refused the mRNA vaccines to be inoculated.